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Heather Dawes highlights some
of the latest genome insights.
The efficient development of
effective vaccines and therapeutics is
perhaps the most challenging of the
myriad promises of post-genomic
biology. Fortunately, as the list of
sequenced bacterial pathogens
grows, so does the opportunity to use
whole genome sequence as a
potentially powerful tool in vaccine
development. 
According to Rino Rappuoli, vice
president of vaccine research at
Chiron, genomic approaches can be
valuable alternatives to conventional,
largely empirical approaches,
especially in cases where strain
variations in surface protein
sequences and cross-reactivity with
human proteins have proven to be
stumbling blocks. Rappouli’s group
published pioneering work last year
in which unassembled genomic
sequence from a virulent Group B
Neisseria meningiditis strain was used
to identify surface-expressed and
exported proteins as novel, conserved
vaccine targets (Science
287:1816-1820). Work using a similar
approach to mine Streptococcus
pneumoniae sequence data was
published earlier this year (Infection
and Immunity 69:1593-1598). Many
other genome-based studies appear
Sequence paves way for new vaccines
Fresh efforts to develop new
vaccines and build stockpiles has
thrown a lifeline to one British
biotech company. Founded by
scientists at Birmingham
University, the company is
spearheading America’s response to
the threat of terrorist attack with
smallpox. Acambis, which has its
headquarters in Cambridge, has
now installed armed security
guards at its laboratories in
Massachusetts after unexpectedly
finding itself in the spotlight since
the events of September 11. 
Developments, however,
predate these events. The company,
which has 160 employees, answered
an advertisement in a trade
newspaper over two years ago to
supply vaccines for stockpiles
maintained by the US Centres for
Disease Control and Prevention. It
won a $343 million deal last year to
supply 40 million doses of its novel
smallpox antidote which was still
undergoing tests. The Americans
were worried that smallpox might
get into the hands of terrorists and
decided to build a stockpile just in
case.
Since September 11, the US
health secretary, Tommy
Thompson, has increased the
contract to 54 million doses and
asked Acambis to bring forward
delivery from 2004 to 2002. He has
even mooted the possibility of
providing an insurance indemnity
to cover side effects, so that
Acambis could speed up
development and need not
complete all the usual clinical
trials. 
Formerly known as Peptide
Therapeutics, the company’s
highest profile project to date was a
drug to reduce the severity of
peanut allergies, which raised the
visibilty of the company,
particularly in the US, but it has so
far not made a profit.
Major pharmaceutical
companies stopped making
smallpox vaccine in the 1980s,
when the world was declared free
of the natural disease. The
traditional vaccine was developed
from cowpox - the cattle version of
the disease. Scrapings from cows
stomachs were a source of vaccine
right up to the 1980s. But Acambis
has developed a way of producing
vaccines using cell cultures in the
laboratory which it is keeping
closely under wraps. Birmingham
University, which no longer has a
stake in Acambis, is set to miss out
on the changed prospects of one of
its spin-off companies.
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the bacterial cell in silico and
predicting the pathogen’s behavior in
different environments. “Clearly that
has to be the long-term goal — to
understand how all these gene
products interact with each other.”
under way, including work on
tuberculosis, malaria, staphylococcus
and chlamydia. 
Ongoing work on plague vaccines
at the UK’s Porton Down facility
illustrates the shift in strategy being
undertaken. A group lead by Rick
Titball has recently seen the
successful completion of phase I
trails by a plague vaccine developed
using relatively empirical approaches
to identifying surface antigens. But
now that the Yersinia pestis genome
sequence is complete the group plans
to use some novel algorithms they’ve
developed this year to mine
sequence data for new, alternative
vaccine targets. Using somewhat
different criteria than have been
conventionally used in such in silico
approaches, the group has come up
with “some very promising leads,”
for new targets, says Titball, who also
points out that the benefits of the
approach could extend to predicting
targets for biodetection systems and
antimicrobial intervention.
